1st approved Symbicort generic, Breyna, now available in US
Aug 7, 2023 · The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available to eligible patients.. Like Symbicort, Breyna is approved as a maintenance therapy to lower airflow obstruction and prevent exacerbations in people with COPD, and for asthma patients, ages 6 and older.
A form of vitamin B3 lowers COPD lung inflammation: Study
Nov 25, 2024 · Assessing inflammation with vitamin B supplement. The University of Copenhagen launched a single-center trial (NCT04990869) at the Respiratory Research Unit at Bispebjerg Hospital in Copenhagen to test nicotinamide riboside against a placebo for its potential as a COPD treatment. The study included 40 adults, mean age 71.9, who had COPD, a history of heavy smoking, and low numbers of ...
Low-dose Morphine Improves Health in COPD Patients With …
Sep 3, 2020 · So, researchers based at the Maastricht University in the Netherlands designed the Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) Phase 4 study (NCT02429050).It investigated whether regular, low-dose, oral sustained-release morphine improved health in COPD patients with moderate-to-very-severe chronic breathlessness.
Ohtuvayre effective across key patient subgroups: ENHANCE trials
Oct 14, 2024 · In an oral presentation titled “Ensifentrine Improved Lung Function, Symptoms, and Quality of Life Regardless of COPD Severity,” Jessica M. Bon, MD, of Wake Forest University School of Medicine, shared Ohtuvarye’s effects in subgroups of ENHANCE participants stratified by COPD severity. The results showed that Ohtuvaryre led to significant improvements in lung function after three months ...
Dupixent (dupilumab) for COPD | COPD News Today
Nov 18, 2024 · Dupixent is a biological therapy, or one made from living organisms. It’s designed to target type 2 inflammation — a type of inflammation marked by elevated eosinophils in the blood and thought to contribute to COPD-related lung inflammation.. The antibody-based treatment specifically blocks the interleukin-4 receptor alpha, which is involved in the signaling of both interleukin-4 and ...
In COPD with type 2 inflammation, exacerbations lowered with...
Sep 16, 2024 · That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by GSK in a company press release.The study tested mepolizumab against a placebo in adults with COPD and type 2 inflammation, which is marked by high blood counts of eosinophils, a type of immune cell.
LupinHaler, generic version of Spiriva HandiHaler, available in US
Aug 28, 2023 · In Europe, generics of Boehringer Ingelheim’s Spiriva HandiHaler began launching in 2021, including ones from Glenmark Pharmaceuticals and Phargentis, but these medications haven’t become available in the U.S.. COPD is a chronic lung disease wherein the airways become blocked, leading to progressively worsening disease symptoms that include shortness of breath and wheezing.
My worsening COPD symptoms have prompted a change of habits
Oct 30, 2024 · Just how long can a person have low oxygen saturation before damage occurs? The answer is unknown. I feel that any amount of time with low oxygen saturation is too long, as expressed in a 2019 COPD News Today article, “Oxygen Manifesto, Part 1: Advice from 3 Respiratory Therapists.”. I’m not sure my oxygen saturation is staying above 88% while using my portable concentrator because I don ...
Ensifentrine, now Ohtuvayre, wins FDA approval for COPD
Jun 27, 2024 · Verona did not specify the list price for the newly approved therapy. According to an analysis from the Institute for Clinical Economic Review (ICER), Ohtuvayre would meet common cost-effectiveness thresholds if its annual price is between $7,500 and $12,700. ICER is a nonprofit organization whose therapy cost-effectiveness assessments increasingly influence price negotiations and ...
COPD trial of Breztri Aerosphere and cardiopulmonary risk opens
Mar 18, 2024 · The THARROS study (NCT06283966) is expected to enroll up to 5,000 COPD patients, ages 40 to 80, with a risk of cardiopulmonary complications at more than 650 centers in the U.S., Canada, and countries in Europe, South America, and Asia.. Participants will be randomly assigned to receive either Breztri Aerosphere or to AstraZeneca’s dual-combination Bevespi Aerosphere (glycopyrronium ...